Online inquiry

IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15582MR)

This product GTTS-WQ15582MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets AXL gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001278599.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 558
UniProt ID M0R0W6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15582MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7911MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK3196165
GTTS-WQ10696MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA M-1095
GTTS-WQ3497MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ12474MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA NN-8226
GTTS-WQ13750MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN 1500
GTTS-WQ2415MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 145
GTTS-WQ6165MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CP-751871
GTTS-WQ3376MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AT-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW